Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial - 29/09/12
, Heikki Joensuu, ProfPhD b, Paul D Nathan, PhD c, Peter G Harper, FRCP d, Marek Z Wojtukiewicz, ProfPhD e, Steve Nicholson, MD f, Amit Bahl, MD g, Piotr Tomczak, PhD h, Seppo Pyrhonen, ProfPhD i, Kate Fife, MD a, Petri Bono, PhD b, Jane Boxall, RN c, Andrea Wagner, MD j, Michael Jeffers, PhD k, Tiffany Lin, PharmD k, David I Quinn, FRACP lSummary |
Background |
Regorafenib inhibits VEGF receptors 1, 2, and 3 and PDGF receptors like other anti-angiogenic tyrosine-kinase inhibitors approved for treatment of advanced renal-cell cancer. Regorafenib also inhibits other potentially important angiogenic kinases like TIE2, activation of which is thought to be important in tumour escape mechanisms. This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma.
Methods |
Patients were recruited from 18 academic oncology centres across Europe and USA. Patients with previously untreated metastatic or unresectable clear-cell renal-cell carcinoma received oral regorafenib (160 mg per day) in repeating cycles of 3 weeks on, 1 week off until disease progression or until patients met the criteria for removal from study. The primary efficacy endpoint was the proportion of patients who achieved an objective overall response, assessed in all patients who were evaluable for response. The trial has finished. This trial is registered with ClinicalTrials.gov, number NCT00664326.
Findings |
The study was done between April 30, 2008, and June 1, 2011. We screened 64 patients, of whom 49 received regorafenib. Median duration of treatment was 7·1 months (range 0·7–34·4, IQR 2·5–18·0) and at the time of data cutoff, six patients (12%) were still receiving treatment. 48 patients were assessable for tumour response. 19 patients (39·6%, 90% CI 27·7–52·5) had an objective response, all of which were partial responses. Drug-related adverse events occurred in 48 patients (98%) and drug-related serious adverse events in 17 (35%). Grade 3 drug-related adverse events were common, most frequently hand and foot skin reaction (16 patients, 33%), diarrhoea (five patients, 10%), renal failure (five patients, 10%), fatigue (four patients, 8%), and hypertension (three patients, 6%). Two patients had grade 4 treatment-related adverse events: two cardiac ischaemia or infarction, one hypomagnesaemia, and one pain in the chest or thorax. Four patients died during study treatment or within 30 days of last dose, of which two were deemed likely to be related to the study drug.
Interpretation |
Regorafenib has antitumour activity as first-line treatment for metastatic or unresectable renal-cell carcinoma. The drug’s safety profile requires close monitoring.
Funding |
Bayer HealthCare Pharmaceuticals.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 10
P. 1055-1062 - octobre 2012 Retour au numéro
Article précédent
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
- Penella J Woll, Peter Reichardt, Axel Le Cesne, Sylvie Bonvalot, Alberto Azzarelli, Harald J Hoekstra, Michael Leahy, Frits Van Coevorden, Jaap Verweij, Pancras CW Hogendoorn, Monia Ouali, Sandrine Marreaud, Vivien HC Bramwell, Peter Hohenberger, for the EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee
- Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
- Alexander Drilon, Natasha Rekhtman, Marc Ladanyi, Paul Paik
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?